A common antibiotic called doxycycline can disrupt the formation of negative thoughts and fears in the brain and may prove useful in treating or preventing post traumatic stress disorder (PTSD), according to research by British and Swiss scientists.
Patients with advanced melanoma who received Bristol-Myers Squibb’s immunotherapies Opdivo and Yervoy had improved overall survival versus those on Yervoy alone.
Vertex Pharmaceuticals Inc. said its Kalydeco cystic fibrosis treatment given with an experimental drug demonstrated significant improvements in lung function in a pair of late-stage trials the company plans to use to seek approval of the combination therapy.
Foamix Pharmaceuticals Ltd. said its experimental acne treatment failed to meet one of two main goals in a late-stage study, pushing its shares down about 42 percent.
Novartis’ heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential blockbuster.
Eli Lilly and Co.’s combination of its experimental breast cancer drug abemaciclib and another widely used treatment slowed disease progression.
Nektar Therapeutics said its experimental opioid succeeded in a key late-stage study.
Catalyst Pharmaceuticals Inc.’s experimental drug to treat patients with a severe form of myasthenia gravis, a rare neuromuscular disease, met the main goals of a study.
Sanofi and Regeneron said results from a one-year test of Dupixent aimed at adults with eczema or moderate-to-severe atopic dermatitis had been positive.
Study data showed patients treated with guselkumab experienced significantly greater improvements compared with the anti-TNF-alpha treatment Humira.